Skip to main content
TipRanks
Go Ultimate75% OFF

Hyundai Pharmaceutical Co., Ltd. (004310) Stock Statistics & Valuation Metrics

Total Valuation

Hyundai Pharmaceutical Co., Ltd. has a market cap or net worth of KRW 201.27B. The enterprise value is KRW 224.18B.

Market Cap
KRW 201.27B
Enterprise Value
KRW 224.18B

Share Statistics

Hyundai Pharmaceutical Co., Ltd. has 32,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
32,000,000
Owned by Insiders
―
Owned by Institutions
0.26%

Financial Efficiency

Hyundai Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.36%.

Return on Equity (ROE)
0.03
Return on Assets (ROA)
0.02
Return on Invested Capital (ROIC)
2.36%
Return on Capital Employed (ROCE)
0.03
Revenue Per Employee
480.69M
Profits Per Employee
6.31M
Employee Count
399
Asset Turnover
1.15
Inventory Turnover
3.48

Valuation Ratios

The current PE Ratio of Hyundai Pharmaceutical Co., Ltd. is 50.23. Hyundai Pharmaceutical Co., Ltd.’s PEG ratio is 0.24.

PE Ratio
50.23
PS Ratio
0.91
PB Ratio
1.45
Price to FCF
27.13
Price to Operating Cash Flow
18.27
PEG Ratio
0.24

Income Statement

In the last 12 months, Hyundai Pharmaceutical Co., Ltd. had revenue of 191.79B and earned 2.52B in profits. Earnings per share was 96.28.

Revenue
191.79B
Gross Profit
78.23B
Operating Income
3.30B
Pretax Income
2.31B
Net Income
2.52B
EBITDA
7.58B
Earnings Per Share (EPS)
96.28

Cash Flow

In the last 12 months, operating cash flow was 10.27B and capital expenditures -3.35B, giving a free cash flow of 6.92B billion.

Operating Cash Flow
10.27B
Free Cash Flow
6.92B
Free Cash Flow per Share
223.72

Dividends & Yields

Hyundai Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 0.46%

Dividend Per Share
―
Dividend Yield
0.46%
Payout Ratio
N/A
Free Cash Flow Yield
3.69%
Earnings Yield
1.92%

Stock Price Statistics

Beta
0.60
52-Week Price Change
61.01%
50-Day Moving Average
7979.60
200-Day Moving Average
7983.68
Relative Strength Index (RSI)
40.61
Average Volume (3m)
4.07M

Important Dates

Hyundai Pharmaceutical Co., Ltd. upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 15, 2026
Next Earnings Date
Feb 18, 2027
Ex-Dividend Date
―

Financial Position

Hyundai Pharmaceutical Co., Ltd. as a current ratio of 1.13, with Debt / Equity ratio of 60.98%

Current Ratio
1.13
Quick Ratio
0.68
Debt to Market Cap
0.52
Net Debt to EBITDA
6.28
Interest Coverage Ratio
1.75

Taxes

In the past 12 months, Hyundai Pharmaceutical Co., Ltd. has paid -209.50M in taxes.

Income Tax
-209.50M
Effective Tax Rate
-0.09

Enterprise Valuation

Hyundai Pharmaceutical Co., Ltd. EV to EBITDA ratio is 21.64, with an EV/FCF ratio of 32.47.

EV to Sales
1.08
EV to EBITDA
21.64
EV to Free Cash Flow
32.47
EV to Operating Cash Flow
21.87

Balance Sheet

Hyundai Pharmaceutical Co., Ltd. has KRW 22.72B in cash and marketable securities with KRW 49.54B in debt, giving a net cash position of -KRW 26.81B billion.

Cash & Marketable Securities
KRW 22.72B
Total Debt
KRW 49.54B
Net Cash
-KRW 26.81B
Net Cash Per Share
-KRW 837.91
Tangible Book Value Per Share
KRW 3,901.28

Margins

Gross margin is 35.56%, with operating margin of 2.59%, and net profit margin of 1.74%.

Gross Margin
35.56%
Operating Margin
2.59%
Pretax Margin
2.29%
Net Profit Margin
1.74%
EBITDA Margin
5.01%
EBIT Margin
2.66%

Analyst Forecast

The average price target for Hyundai Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
11.35%
EPS Growth Forecast
204.54%

Scores

Smart Score
―
AI Score
52